- Home
- CELC
CELC
Celcuity Inc.
as 07-26-2024 4:00pm EST
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | MINNEAPOLIS |
| Market Cap: | 600.6M | IPO Year: | 2017 |
| Target Price: | $29.20 | AVG Volume (30 days): | 449.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.39 - $22.19 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Celcuity Inc. (CELC)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Buller Richard E | CELC | Director | Jun 21 '24 | Sell | $15.68 | 350 | $5,488.00 | 7,381 | SEC Form 4 |
| Buller Richard E | CELC | Director | Apr 24 '24 | Sell | $17.06 | 350 | $5,971.00 | 7,731 | SEC Form 4 |
| Buller Richard E | CELC | Director | Feb 21 '24 | Sell | $14.15 | 350 | $4,952.50 | 8,081 | SEC Form 4 |
| Buller Richard E | CELC | Director | Dec 20 '23 | Sell | $14.37 | 350 | $5,029.50 | 8,431 | SEC Form 4 |
| Dalvey David | CELC | Director | Dec 14 '23 | Sell | $14.75 | 5,000 | $73,751.50 | 227,940 | SEC Form 4 |
| Dalvey David | CELC | Director | Dec 14 '23 | Sell | $14.57 | 2,940 | $42,847.27 | 225,000 | SEC Form 4 |
| Dalvey David | CELC | Director | Dec 12 '23 | Sell | $14.61 | 2,060 | $30,089.18 | 237,940 | SEC Form 4 |
| Dalvey David | CELC | Director | Dec 12 '23 | Sell | $14.50 | 5,000 | $72,500.00 | 232,940 | SEC Form 4 |
| Dalvey David | CELC | Director | Dec 7 '23 | Sell | $14.85 | 5,000 | $74,250.00 | 245,000 | SEC Form 4 |
| Dalvey David | CELC | Director | Dec 7 '23 | Sell | $15.00 | 5,000 | $75,000.00 | 240,000 | SEC Form 4 |
Latest Celcuity Inc. News
CELC Breaking Stock News: Dive into CELC Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
Leerink Partners Starts Celcuity With Outperform Rating, $29 Price Target
CNW Group
2 months ago
Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
PR Newswire
2 months ago
IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
Business Wire
2 months ago
Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store
AFP
2 months ago
New Zealand scraps plan to tax livestock burps, farts
The Wall Street Journal
2 months ago
ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility
Business Wire
2 months ago
InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA
Bloomberg
2 months ago
UK Unemployment Rises in Sign Inflationary Pressures Cool
Compare CELC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CELC Celcuity Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.